EVAX · NASDAQ

Evaxion A (EVAX) Stock Price & Fundamentals

$458.15+0.77%+$3.49End-of-day price as of Oct 9, 2026

Sample prices

Prices on this page are generated sample data for development, not real market data, so market cap, P/E and dividend yield are illustrative too. Fundamentals are real, from Evaxion A's SEC filings.

Evaxion A (EVAX) closed at $458.15 on Oct 9, 2026, up 0.77% from the previous close of $454.66.

Share price, past year

1Y +3.89%

Daily closing prices

52-week range $355.55 – $458.15.

Monthly closing prices

Last closing price of each month
Date	Close
Oct 9, 2026	$458.15
Sep 30, 2026	$438.65
Aug 31, 2026	$447.84
Jul 31, 2026	$432.10
Jun 30, 2026	$418.43
May 29, 2026	$393.34
Apr 30, 2026	$385.04
Mar 31, 2026	$362.99
Feb 27, 2026	$372.01
Jan 30, 2026	$362.28
Dec 31, 2025	$392.86
Nov 28, 2025	$418.63
Oct 31, 2025	$434.29

Key statistics

Market cap: —
P/E (TTM): —
EPS (TTM): —
Revenue (TTM): —
Net income (TTM): —
Shares outstanding: 417M
Dividend yield: —
52-week range: $355.55 – $458.15

Market cap, P/E and dividend yield aren't shown for Evaxion A yet: its SEC filings count its ordinary shares, which can differ from the shares traded in the US.

Financials

Evaxion A reported revenue of $7.53M for fiscal 2025, up 125.12% from fiscal 2024.

Evaxion A reported a net loss of $7.71M in fiscal 2025.

Annual revenue

FY22FY23FY24FY25

Evaxion A annual financials by fiscal year, from SEC filings
Fiscal year	Revenue	Growth	Net income	Net margin	EPS (diluted)	Free cash flow
FY2025ended Dec 31, 2025	$7.53M	+125.1%	−$7.71M	−102.4%	−$0.02	−$6.64M
FY2024ended Dec 31, 2024	$3.34M	+4,480.8%	−$10.57M	−316.0%	−$0.20	−$12.94M
FY2023ended Dec 31, 2023	$73.00K	—	−$22.13M	−30,308.2%	−$0.81	−$17.78M
FY2022ended Dec 31, 2022	$0.00	—	−$23.17M	—	−$0.98	−$26.07M

Evaxion A quarterly results
Quarter	Revenue	Net income	EPS (diluted)
Q2 FY2025ended Jun 30, 2025	$37.00K	−$4.83M	−$0.02
Q2 FY2024ended Jun 30, 2024	$154.00K	−$6.20M	−$0.12
Q2 FY2023ended Jun 30, 2023	$0.00	−$5.68M	−$0.21

Earnings

Evaxion A lost $0.02 per share in fiscal Q2 2025, compared with a loss of $0.12 a year earlier.

Diluted earnings per share by quarter

Q1'21Q2'21Q1'22Q2'22Q2'23Q2'24Q2'25

Evaxion A quarterly earnings per share, from SEC filings
Quarter	Reported	EPS (diluted)	A year earlier	Change
Q2 FY2025ended Jun 30, 2025	—	−$0.02	−$0.12	—
Q2 FY2024ended Jun 30, 2024	—	−$0.12	−$0.21	—
Q2 FY2023ended Jun 30, 2023	—	−$0.21	−$0.20	—
Q2 FY2022ended Jun 30, 2022	—	−$0.20	−$0.36	—
Q1 FY2022ended Mar 31, 2022	—	−$0.25	−$0.23	—
Q2 FY2021ended Jun 30, 2021	—	−$0.36	—	—
Q1 FY2021ended Mar 31, 2021	—	−$0.23	—	—

Company profile

Name: Evaxion A/S
Ticker: EVAX
Exchange: NASDAQ
Industry (SEC SIC): Biological Products, (No Diagnostic Substances)
Headquarters: Dr Neergaards Vej 5f, Hoersholm
Incorporated in: G7
Fiscal year ends: December
SEC CIK: 0001828253

Recent SEC filings

20-FAnnual report for period ending Dec 31, 2025
Mar 5, 2026
20-FAnnual report for period ending Dec 31, 2024
Apr 1, 2025
20-FAnnual report for period ending Dec 31, 2023
Mar 26, 2024
20-FAnnual report for period ending Dec 31, 2022
Apr 28, 2023
20-FAnnual report for period ending Dec 31, 2021
Mar 31, 2022
20-FAnnual report for period ending Dec 31, 2020
Apr 7, 2021

Evaxion A's industry, as the SEC classifies it, is Biological Products, (No Diagnostic Substances). The companies in it closest to Evaxion A in revenue are Fate Therapeutics, Curis and Taysha Gene Therapies.

Frequently asked questions

What is Evaxion A's stock price?